JP5547637B2 - 浮腫を治療または軽減するための新規な化合物およびその使用方法 - Google Patents

浮腫を治療または軽減するための新規な化合物およびその使用方法 Download PDF

Info

Publication number
JP5547637B2
JP5547637B2 JP2010527904A JP2010527904A JP5547637B2 JP 5547637 B2 JP5547637 B2 JP 5547637B2 JP 2010527904 A JP2010527904 A JP 2010527904A JP 2010527904 A JP2010527904 A JP 2010527904A JP 5547637 B2 JP5547637 B2 JP 5547637B2
Authority
JP
Japan
Prior art keywords
edema
oligonucleotide compound
oligonucleotide
treatment
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010527904A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539974A5 (https=
JP2010539974A (ja
Inventor
ザルガリ，アレゾウ
アクセレッソン，ラース−ヨラン
スピーク，アン−クリスティン
コウズネットソフ，ニコライ
Original Assignee
インデックス・ファーマシューティカルズ・アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インデックス・ファーマシューティカルズ・アクチエボラーグ filed Critical インデックス・ファーマシューティカルズ・アクチエボラーグ
Publication of JP2010539974A publication Critical patent/JP2010539974A/ja
Publication of JP2010539974A5 publication Critical patent/JP2010539974A5/ja
Application granted granted Critical
Publication of JP5547637B2 publication Critical patent/JP5547637B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
JP2010527904A 2007-10-05 2008-10-02 浮腫を治療または軽減するための新規な化合物およびその使用方法 Expired - Fee Related JP5547637B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97801007P 2007-10-05 2007-10-05
US60/978,010 2007-10-05
PCT/SE2008/000542 WO2009045145A1 (en) 2007-10-05 2008-10-02 Novel compounds for the treatment or alleviation of edema, and methods for their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014101486A Division JP5914567B2 (ja) 2007-10-05 2014-05-15 浮腫を治療または軽減するための新規な化合物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2010539974A JP2010539974A (ja) 2010-12-24
JP2010539974A5 JP2010539974A5 (https=) 2011-11-10
JP5547637B2 true JP5547637B2 (ja) 2014-07-16

Family

ID=40526448

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010527904A Expired - Fee Related JP5547637B2 (ja) 2007-10-05 2008-10-02 浮腫を治療または軽減するための新規な化合物およびその使用方法
JP2014101486A Expired - Fee Related JP5914567B2 (ja) 2007-10-05 2014-05-15 浮腫を治療または軽減するための新規な化合物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014101486A Expired - Fee Related JP5914567B2 (ja) 2007-10-05 2014-05-15 浮腫を治療または軽減するための新規な化合物およびその使用方法

Country Status (7)

Country Link
US (1) US8410068B2 (https=)
EP (2) EP2207555B1 (https=)
JP (2) JP5547637B2 (https=)
CA (1) CA2738070C (https=)
DK (1) DK2656850T3 (https=)
ES (1) ES2600919T3 (https=)
WO (1) WO2009045145A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573176B1 (en) * 2007-05-04 2016-04-06 InDex Pharmaceuticals AB Tumour growth inhibitory compounds and methods of their use
EP2288702A4 (en) * 2008-06-18 2011-06-29 Index Pharmaceuticals Ab COMBINATION THERAPIES AGAINST CANCER
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
US8637479B2 (en) 2008-11-04 2014-01-28 Index Pharmaceuticals Ab Compounds and methods for the treatment of inflammatory diseases of the CNS
EP3165607B1 (en) * 2010-12-21 2021-04-07 InDex Pharmaceuticals AB Biologically active oligonucleotides capable of modulating the immune system
WO2012084991A1 (en) * 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Biologically active oligonucleotides capable of modulating the immune system ii
US10975033B2 (en) * 2011-07-12 2021-04-13 Vanderbilt University Methods for treating inflammation and hypertension with γ-ketoaldehyde skavengers
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610289A (en) * 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
DE69232722T2 (de) * 1991-08-23 2002-12-05 The Board Of Regents Of The University Of Nebraska, Lincoln Verfahren und zusammensetzungen für zelluläre reprogrammierung
US7517644B1 (en) * 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
US5968826A (en) * 1998-10-05 1999-10-19 Isis Pharmaceuticals Inc. Antisense inhibition of integrin α4 expression
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
WO2002012894A1 (en) * 2000-08-09 2002-02-14 Mount Sinai School Of Medicine Kruppel-like factor 6 (klf6), a tumorsuppressor protein, and dia gnostics, therapeutics, and screening based on this protein
US7630836B2 (en) * 2001-05-30 2009-12-08 The Kitasato Institute Polynucleotides
AU2003303305A1 (en) * 2002-10-02 2004-09-30 Nuvelo,Inc. Novel nucleic acids and polypeptides
CN1711361A (zh) * 2002-10-15 2005-12-21 诺瓦提斯公司 预测药物治疗副效应水肿的方法
JP2004166699A (ja) * 2002-11-06 2004-06-17 Takeda Chem Ind Ltd 抗利尿剤
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US8227193B2 (en) * 2003-10-01 2012-07-24 The Regents Of The University Of California Compositions and methods for gene expression
US7374927B2 (en) 2004-05-03 2008-05-20 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples
PL2179737T3 (pl) * 2005-07-01 2014-01-31 Index Pharmaceuticals Ab Sposób do modulowania wrażliwości na steroidy
AU2006278282A1 (en) * 2005-08-09 2007-02-15 University Of Virginia Patent Foundation Methods and compositions for inhibition of vascular permeablility
EP2573176B1 (en) * 2007-05-04 2016-04-06 InDex Pharmaceuticals AB Tumour growth inhibitory compounds and methods of their use

Also Published As

Publication number Publication date
JP2014204722A (ja) 2014-10-30
EP2207555A4 (en) 2010-11-24
WO2009045145A1 (en) 2009-04-09
EP2656850B1 (en) 2016-07-27
EP2656850A2 (en) 2013-10-30
JP5914567B2 (ja) 2016-05-11
US20100240736A1 (en) 2010-09-23
EP2207555B1 (en) 2013-07-24
EP2207555A1 (en) 2010-07-21
JP2010539974A (ja) 2010-12-24
CA2738070C (en) 2018-03-20
ES2600919T3 (es) 2017-02-13
DK2656850T3 (en) 2016-11-28
EP2656850A3 (en) 2014-02-12
CA2738070A1 (en) 2009-04-09
US8410068B2 (en) 2013-04-02

Similar Documents

Publication Publication Date Title
JP5914567B2 (ja) 浮腫を治療または軽減するための新規な化合物およびその使用方法
JP2023178518A (ja) シクロデキストリンを使用するための方法
JP2018203747A5 (https=)
CN110461862A (zh) 用于治疗由衰老细胞介导的病症和用于治疗癌症的基于肽的蛋白酶体抑制剂
CN107108685A (zh) miR‑29模拟物及其用途
CN105008394A (zh) 治疗结肠直肠癌的方法
JP5749651B2 (ja) 多形核細胞の動員および／または遊走を減少させる化合物および方法
CN110564842B (zh) 细胞色素酶cyp26a1在制备治疗神经病理性疼痛的药物中的应用
JP6238319B2 (ja) 創傷または線維症の治療剤
JP5788907B2 (ja) 疾患の治療に使用される化合物
CN104083761A (zh) microRNA-101抑制剂在制备预防或治疗骨关节炎药物中的应用
CA3043103C (en) Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
EP4176887B1 (en) Pharmaceutical composition for prevention or treatment of inflammatory bowel disease comprising organoid and anti-inflammatory agent
CN115381950B (zh) Rab 35或其下游调控分子在治疗骨折后慢性疼痛中的应用
US20180086827A1 (en) Therapeutics and methods of treating fibroproliferative diseases
Benardeau et al. The Novel Soluble Guanylyl Cyclase (sGC) Activator Runcaciguat Induced Renal Vasodilation and Reduced Kidney Damage in a Rat CKD Model: PO0600
Chen et al. Histone Deacetylase 6 Inhibition Mitigates Renal Fibrosis by Suppressing TGF-β/SMAD3 and eGFR Signaling Pathways: PO0602
Mori et al. Inhibition of KIM-1-Mediated Fatty Acid Uptake by a Novel Inhibitor Attenuates Pro-Fibrotic Responses in Multiple Models of Human Primary Kidney Epithelial Cells Including Kidney Tubuloids: PO0601
Douglas Nam et al. Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis 2
JP2013237649A (ja) 炎症性関節疾患治療薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140515

R150 Certificate of patent or registration of utility model

Ref document number: 5547637

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees